Drug intelligence / Profile preview

Product 0405

Development stage: Discontinued
Lead developer: Fougera Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Product 0405 is a pharmaceutical product initially developed by Novartis Pharma AG for the treatment of atopic dermatitis. The drug reached Phase 3 clinical trials but was ultimately discontinued. Clinical trials were being conducted to evaluate its safety and efficacy in pediatric and adolescent subjects with mild to moderate atopic dermatitis.

Beyond the preview

Go deeper on Product 0405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Product 0405.

Explore the full profile